Mr. Reginald R Jones, PHARMACIST Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1248 Main St, Fyffe, AL 35971 Phone: 256-638-6667 Fax: 256-638-6658 |
Cheree Reed Rains, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 44 Blackwell St, Fyffe, AL 35971 Phone: 256-623-2944 Fax: 256-623-3938 |
Tiffany Simpson Mcfall Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1248 Main St, Fyffe, AL 35971 Phone: 256-638-6667 Fax: 256-638-6658 |
Ashley Bryant Holcomb, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1248 Main St, Fyffe, AL 35971 Phone: 256-638-6667 Fax: 256-638-6658 |
Brandon Lee Rains, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 44 Blackwell St, Fyffe, AL 35971 Phone: 256-623-2944 Fax: 256-623-3938 |
News Archive
Correctly and quickly diagnosing malaria is essential for effective and life-saving treatment. But rapid detection, particularly in remote areas, is not always possible because current methods are time-consuming and require precise instrumentation and highly skilled microscopic analysis. Now, a promising new optical imaging system, described in a paper published today in the Optical Society's (OSA) open-access journal Biomedical Optics Express, may make the diagnosis of this deadly disease much easier, faster, and more accurate.
Obese adults with excess visceral fat (fat located inside the abdominal cavity, around the body's internal organs) and biomarkers of insulin resistance had an associated increased risk for the development of type 2 diabetes mellitus, while obese individuals with higher amounts of total body fat and subcutaneous fat (underneath the skin) did not have this increased risk, according to a study in the September 19 issue of JAMA, and theme issue on obesity.
Combined folic acid, vitamin B6 and vitamin B12 supplements had no statistically significant effect on the risk of colorectal adenoma among women who were at high risk for cardiovascular disease, according to a study published October 12 in the Journal of the National Cancer Institute.
Tris Pharma, Inc. announced that U.S. Food and Drug Administration has accepted for review its New Drug Application ("NDA") for Dyanavel XR (amphetamine) CII, an Extended-Release Oral Suspension.
› Verified 5 days ago